Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Mesirow Institutional Investment Management Inc.

Mesirow Institutional Investment Management Inc. trimmed its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 7.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 742,295 shares of the biopharmaceutical company's stock after selling 58,503 shares during the quarter. Catalyst Pharmaceuticals makes up about 1.2% of Mesirow Institutional Investment Management Inc.'s portfolio, making the stock its 29th biggest position. Mesirow Institutional Investment Management Inc. owned 0.62% of Catalyst Pharmaceuticals worth $15,492,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of CPRX. Summit Investment Advisors Inc. lifted its position in shares of Catalyst Pharmaceuticals by 5.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company's stock worth $244,000 after purchasing an additional 580 shares during the last quarter. Bank of Montreal Can grew its stake in Catalyst Pharmaceuticals by 6.2% in the 4th quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company's stock worth $311,000 after acquiring an additional 875 shares in the last quarter. Rhumbline Advisers increased its position in shares of Catalyst Pharmaceuticals by 0.3% during the fourth quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company's stock worth $6,518,000 after acquiring an additional 952 shares during the period. Handelsbanken Fonder AB boosted its holdings in shares of Catalyst Pharmaceuticals by 2.9% in the fourth quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company's stock valued at $740,000 after purchasing an additional 1,000 shares during the period. Finally, Xponance Inc. grew its stake in Catalyst Pharmaceuticals by 6.8% in the fourth quarter. Xponance Inc. now owns 18,763 shares of the biopharmaceutical company's stock worth $392,000 after purchasing an additional 1,189 shares in the last quarter. 79.22% of the stock is owned by institutional investors.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 44,904 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares in the company, valued at $1,521,404.57. This trade represents a 39.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

CPRX stock traded up $0.07 during trading on Thursday, reaching $23.19. The company had a trading volume of 576,941 shares, compared to its average volume of 1,108,125. The company has a market cap of $2.83 billion, a price-to-earnings ratio of 19.65, a price-to-earnings-growth ratio of 3.31 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a twelve month low of $14.47 and a twelve month high of $26.16. The firm has a 50-day simple moving average of $22.57 and a 200-day simple moving average of $22.14.

Analyst Ratings Changes

Several equities research analysts have weighed in on CPRX shares. Stephens reiterated an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Bank of America reaffirmed a "buy" rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Robert W. Baird lifted their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, March 3rd. Finally, Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Catalyst Pharmaceuticals has a consensus rating of "Buy" and an average target price of $32.29.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.